Specialist neuro-oncology second opinions on brain and spine MRI and CT
Radiology Prime provides independent neuro-oncology second opinions on MRI and CT imaging of the brain, spine, and skull base. Reports are personally prepared within 24 hours by our Clinical Lead, a European-registered consultant neuroradiologist, applying sub-specialty frameworks including RANO criteria for treatment response assessment, to support discussion with your treating physician.
The structured report is designed to complement your treating team’s review, providing an independent sub-specialty interpretation that may help clarify imaging findings in tumour assessment, treatment response, and follow-up.
Why independent sub-specialty review can change your diagnostic conversation
Imaging in neuro-oncology is among the most interpretatively demanding work in radiology. Distinguishing treatment effect from true tumour progression, characterising a newly discovered lesion, and assessing subtle interval change across serial scans all benefit from the focused experience that sub-specialty review can bring.
An independent neuro-oncology second opinion may help clarify findings, surface alternative considerations, and reduce interpretive variability in cases where the initial report leaves questions unresolved.
Your scans are reviewed by our Clinical Lead, a consultant radiologist (Facharzt für Radiologie) with a sub-specialty focus in neuroradiology and over ten years of senior experience, formerly Chief Resident in Neuroradiology at University Hospital Freiburg.
Common diagnostic challenges in neuro-oncology
Neuro-oncology imaging sits at the intersection of tumour biology, treatment effect, and normal anatomical variation. Several specific challenges recur across cases and are the situations where sub-specialty review tends to add the most value.
Pseudoprogression after chemoradiation
In the months following concurrent chemoradiation for high-grade glioma, new or enlarging enhancement may represent true tumour progression or treatment-related pseudoprogression. The two can look similar on a single post-treatment scan, and the distinction materially affects oncology decision-making. Structured application of RANO criteria, attention to timing relative to radiation, and comparison across serial imaging may help clarify the interpretation.
Radiation necrosis versus tumour recurrence
Late radiation necrosis can mimic recurrent disease on contrast-enhanced MRI, and the imaging features overlap substantially. Advanced sequences such as perfusion imaging, MR spectroscopy, and diffusion characteristics may favour one interpretation over the other, but the findings are rarely definitive. A sub-specialty review may help weigh the competing features and frame the discussion your treating team will have about next steps.
Small metastases and the limits of a single scan
Brain metastases from systemic cancer may be small, multiple, and distributed in ways that test the sensitivity of any single read. Sequence selection, contrast timing, and susceptibility-weighted imaging all contribute to detection. A structured sub-specialty review may help ensure that subtle lesions are identified and characterised in the context of the primary malignancy and treatment history.
Incidental lesions and the characterisation question
A meningioma, a pituitary lesion, or a vestibular schwannoma may be discovered incidentally on imaging performed for an unrelated reason. The clinical question then becomes whether the finding warrants active management, serial follow-up, or reassurance. Imaging features including location, enhancement pattern, growth rate across comparison studies, and relationship to adjacent structures may inform this discussion, but the interpretation benefits from sub-specialty familiarity with the full differential.
Interpretation quality in neuro-oncology may vary with sub-specialty experience and case complexity. Our Clinical Lead aims to deliver a structured neuro-oncology report within 24 hours, applying the frameworks and comparative discipline that this imaging sub-specialty requires.
How it works
Get your expert second opinion radiology report in 3 simple steps
Upload your medical scans
Send us your scan images and specific questions, we’ll take care of the rest.
Expert radiologist review
Certified radiologists provide a detailed, easy-to-understand report with your diagnosis and treatment suggestions.
Get results within 24 hours
Receive your report quickly. Talk or message your radiologist directly to discuss your results.
View a Sample Neuroradiology Report
Transparency is key to trust. View a redacted sample of an second opinion report. In this case, the MRI findings were interpreted as more consistent with a non-demyelinating process rather than active multiple sclerosis.
Get greater diagnostic clarity with specialist neuro-oncology insight
An independent sub-specialty review can provide additional clarity in complex neuro-oncology cases. You receive a structured report within 24 hours, with imaging insights framed to support informed clinical discussions with your treating physician.
Glioma assessment and follow-up
Our Clinical Lead reviews imaging for primary glial tumours, including low-grade and high-grade gliomas. Findings are interpreted with attention to enhancement patterns, diffusion characteristics, and interval change across serial scans, with framework-based response assessment where applicable.
Brain metastases from systemic cancer
For patients with known or suspected metastatic disease, imaging is reviewed for lesion number, distribution, size, and treatment response. Interpretation considers the primary malignancy, prior treatment, and the clinical question your treating team is working on.
Post-treatment response: RANO-based review
For patients in follow-up after chemoradiation, targeted therapy, or stereotactic radiosurgery, our Clinical Lead applies RANO criteria to assess response and may help distinguish features favouring true progression from features favouring pseudoprogression or treatment effect.
Meningioma and skull base lesion characterisation
Meningiomas and other extra-axial and skull base lesions are reviewed with attention to typical and atypical imaging features, relationship to adjacent neurovascular structures, and interval change where comparison imaging is available. Findings are framed to support your treating team’s management discussion.
Pituitary and sellar region lesions
Macroadenomas, microadenomas, Rathke cleft cysts, and other sellar and parasellar lesions are reviewed with attention to size, extension, optic apparatus involvement, and relationship to cavernous sinus structures. Imaging features are interpreted in the context of any available endocrine or clinical information.
Spinal cord and intradural tumours
Imaging for intramedullary tumours, intradural extramedullary lesions, and drop metastases is reviewed with attention to lesion location, cord involvement, and relevant anatomical relationships. The report supports the neurosurgical and oncology discussion your treating team is having.
Frequently asked questions
A second opinion does not make treatment decisions, but it may clarify the imaging findings that inform them. The report provides an independent sub-specialty interpretation, with framework-based response assessment where applicable, which may surface considerations your treating team will want to weigh. Any treatment decisions remain with you and your treating physician, informed by the full clinical picture that only they have access to.
Yes. The report is written as a peer-to-peer document for your treating team as well as a patient-accessible document for you. Many patients share the report with their oncologist ahead of the next multidisciplinary team discussion, and the structured format is designed to support that conversation.
Yes. For patients in follow-up after treatment for glioma or brain metastases, our Clinical Lead can apply RANO criteria to assess response where the imaging protocol and comparison studies support it. The assessment is framed as an independent sub-specialty interpretation intended to complement your oncology team’s review, not to replace it. We recommend sharing the report with your treating oncologist to inform the next discussion.
Yes, and we strongly encourage it. Serial comparison is central to neuro-oncology imaging, and a single scan reviewed in isolation is rarely as informative as the same scan read against prior studies. You add any prior imaging once you have uploaded your case.
No. Patients can request a neuro-oncology second opinion directly, without a referral from their treating physician. We do recommend that you share the report with your treating team afterwards, because the report is designed to support your clinical discussion rather than to stand alone.
Mid-treatment cases are among the situations where sub-specialty review is most useful, because response assessment is where framework discipline matters most. We review imaging from any point in the treatment course, with attention to the timing of imaging relative to chemoradiation, targeted therapy, or stereotactic radiosurgery. Share the report with your treating team before any change to your treatment plan.
If the report surfaces imaging considerations that differ from or add to your treating team’s interpretation, the appropriate next step is to share the report with them and ask for a discussion. A second opinion is a discussion point, not a diagnostic endpoint, and your treating team is best placed to integrate any new imaging considerations with the full clinical picture.
The report includes a clinical context summary, a structured findings section, an impression framed as discussion points, and recommendations for questions to raise with your treating physician. Where applicable, the report cites specific frameworks such as RANO criteria and explains their application to your case. A plain-language summary section is included for patient understanding. We also answer any questions you have.
The report is layered for two audiences: a sub-specialty radiology section written for your treating physician, and a plain-language summary section written for you. Clinical terminology is used where accuracy requires it, but the patient summary makes the key points accessible. If any part of the report raises questions, those are exactly the questions to bring to your treating physician.